Category:

Boston Scientific to Acquire Nalu Medical for $533 Million to Expand Chronic Pain Portfolio

Posted on by cpatches

Deal strengthens neuromodulation lineup with battery-free neurostimulation system

Boston Scientific Corporation (NYSE: BSX) announced Friday that it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company specializing in minimally invasive treatments for chronic pain.

Under the terms of the agreement, Boston Scientific will pay approximately $533 million in cash for the remaining equity of Nalu Medical that it does not already own. The company has been a strategic investor in Nalu since 2017. The transaction, expected to close in the first half of 2026, remains subject to customary closing conditions.

Nalu’s flagship product, the Nalu Neurostimulation System, is designed to deliver targeted relief for adults suffering from severe, intractable chronic pain of peripheral nerve origin — including pain in the shoulder, lower back, and knee. The system delivers mild electrical impulses to interrupt pain signals before they reach the brain and features a miniaturized, battery-free implantable pulse generator powered wirelessly by an external therapy disc and controlled via a smartphone app.

The U.S. Food and Drug Administration cleared the Nalu system in 2019. Results from the COMFORT and COMFORT 2 clinical trials demonstrated significant and sustained pain reduction, with 87% of participants in the first trial reporting more than 50% pain reduction at 12 months and 79% in the second trial achieving an average 64% reduction at six months. Real-world data from over 2,000 patients reinforced these outcomes, with 94% experiencing clinically meaningful improvement.

“Peripheral nerve stimulation is an exciting field with a significant unmet patient need,” said Jim Cassidy, president of Neuromodulation at Boston Scientific. “Adding Nalu Medical’s highly differentiated technology complements our existing therapies — including spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation — and enables us to deliver advanced pain relief options to a wider variety of patient populations.”

Boston Scientific expects Nalu to generate over $60 million in sales in 2025 and to deliver growth exceeding 25% in 2026. The acquisition is projected to be immaterial to adjusted EPS in 2026, slightly accretive in 2027, and increasingly accretive thereafter. On a GAAP basis, the company expects the deal to be more dilutive due to amortization and acquisition-related expenses.

Nalu Medical, headquartered in Carlsbad, California, has been repeatedly recognized for innovation, including being named among the top 100 new products globally by R&D Magazine and winning multiple Medical Design Excellence Awards. Its compact, modular neurostimulation system represents a next-generation approach to chronic pain management by reducing the need for frequent interventions and improving patient comfort.

Boston Scientific, based in Marlborough, Massachusetts, is a global medical technology leader with a 45-year history of advancing science and developing solutions that improve patient outcomes across multiple therapeutic areas.

Rani Therapeutics Soars on $1 Billion Chugai Partnership and $60 Million Private Placement

Posted on by cpatches

Massive trading volume follows dual announcements boosting balance sheet and strategic outlook

Rani Therapeutics Holdings (NASDAQ: RANI) surged more than 200% in early trading Friday, with over 240 million shares changing hands — a dramatic increase from its three-month average daily volume of just over 600,000. The spike follows back-to-back announcements of a major collaboration agreement with Chugai Pharmaceutical Co. worth up to $1.085 billion and an oversubscribed $60.3 million private placement.

The collaboration with Japan-based Chugai — a member of the Roche Group — covers multiple high-value therapeutic programs, including those in rare diseases and immunology. Under the deal, Rani will receive a $10 million upfront payment and is eligible for up to $75 million in technology transfer and development milestones, $100 million in sales milestones, and single-digit royalties on future product sales. Chugai also has the option to partner on up to five additional drug targets under similar terms, which could bring the total potential deal value to more than $1 billion.

“This partnership represents a convergence of Rani’s cutting-edge oral delivery platform and Chugai’s expertise in antibody development,” said Rani Therapeutics CEO Talat Imran. “We’re uniting two powerful scientific teams to develop oral therapies that could redefine treatment for rare and immunologic diseases globally.”

Alongside the collaboration, Rani announced a $60.3 million private placement priced at-the-market under Nasdaq rules, led by new investor Samsara and joined by RA Capital Management, Anomaly, Special Situations Funds, Invus, and Rani’s Executive Chairman Mir Imran. The oversubscribed financing includes 42.6 million shares of Class A common stock and 82.4 million pre-funded warrants, each accompanied by warrants to purchase additional shares.

Rani said the net proceeds from the offering, combined with the upfront and milestone payments from Chugai, will extend its operating runway into 2028 and fund advancement of its RaniPill® platform — a proprietary oral delivery system designed to replace subcutaneous or intravenous biologic injections with oral capsules.

“We believe this additional financing from leading biotech investors reflects growing confidence in our strategy,” said Imran. “Together, this financing and our strategic partnership with Chugai mark a pivotal moment for Rani.”

At the closing of the financing, Samsara and Anomaly will each have the right to appoint a member to Rani’s board of directors.

Rani Therapeutics, based in San Jose, California, is a clinical-stage biotherapeutics company focused on developing orally administered biologics and drugs using its RaniPill® platform technology.

Release – GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Presentations Underscore Favorable Safety Profile and Robust T-Cell Responses of GEO-CM04S1 in Vulnerable Populations

ATLANTA, GA – October 16, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced presentations by its senior scientific leadership at the World Vaccine Congress Europe 2025, held October 13–16 at the RAI Amsterdam Convention Centre in Amsterdam, Netherlands.

Presentation Highlights

Mark J. Newman, PhD – Chief Scientific Officer
Workshop Presentation: “Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity – Broader specificity – Increased memory.”

  • Highlighted the limitations of current “one-size-fits-all” vaccines for immunocompromised populations.
  • Presented Phase 2 data showing GEO-CM04S1 elicits strong T-cell responses to both Spike (S) and Nucleocapsid (N), exceeding responses induced by mRNA boosters.
  • Demonstrated broad, durable immunity in preclinical and early clinical data, including responses against Omicron subvariants.
  • Reinforced the potential of GEO-CM04S1 to provide longer-lasting protection and reduce the need for frequent vaccine reformulations.

Kelly T. McKee, Jr., MD, MPH – Chief Medical Officer
Poster Presentation: “Interim Safety and Reactogenicity of GEO-CM04S1, an MVA-vectored, multi-antigen COVID-19 vaccine, in adults with hematologic malignancies receiving cellular therapies.”

  • Reported interim safety results from a Phase 2 trial in patients with hematologic malignancies post-hematopoietic stem cell transplant or chimeric antigen receptor (CAR)-T cell therapy.
  • GEO-CM04S1 showed a safety profile comparable to mRNA vaccines, with only mild-to-moderate treatment-emergent adverse events, predominantly injection site reactions, fatigue, and myalgia… observed.
  • No vaccine-related serious adverse events, myocarditis, or pericarditis have been reported to date.
  • Breakthrough infections occurred but were mild-to-moderate in severity.

“These data continue to support our conviction that GEO-CM04S1 has the potential to fill a critical gap for immunocompromised patients who are not adequately protected against severe COVID-19 by existing vaccines,” said David Dodd, Chairman & CEO of GeoVax. “Our MVA-based, multi-antigen approach is designed to provide broader, more durable protection, and we are encouraged by the consistent safety profile emerging across the ongoing trials.”

About GEO-CM04S1

GEO-CM04S1 is a synthetic, next-generation COVID-19 vaccine candidate that co-expresses spike (S) and nucleocapsid (N) antigens using GeoVax’s MVA vector platform. Designed to induce both antibody and T-cell responses, GEO-CM04S1 is being evaluated in three Phase 2 clinical trials:

  1. As a primary vaccine for immunocompromised individuals (including post-transplant and hematologic cancer patients),
  2. As a booster for patients with chronic lymphocytic leukemia (CLL), and
  3. As a durable booster for healthy adults previously immunized with mRNA vaccines

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

info@geovax.com

678-384-7220

Media Contact:

Jessica Starman

media@geovax.com 

Nicola Mining Inc. (HUSIF) – Hitting All the Right Notes

Posted on by cpatches


Thursday, October 16, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Treasure Mountain exploration. Nicola Mining Inc. (OTCQB: HUSIF, TSXV: NIM) provided an update on its plan for 2026 exploration drilling at the Treasure Mountain Silver Project. The area of exploration interest is northwest of the currently suspended mine and consists of several northeast to southwest trending and steeply dipping sulphide-rich veins. Results from previous exploration work confirmed the presence of vein-hosted silver, copper, lead, zinc, and gold, providing support for initial diamond drilling to establish the width of the trend and mineralization at depth.

Recent gold sales. Talisker Resources (OTCQB: TSKFF, TSX: TSK) has an agreement to process run-of-mine material from its Mustang Mine at Nicola’s Merritt Mill. For the quarter ending on September 30, a total of 1,569 ounces of gold were produced from Talisker’s Mustang Mine. Nicola receives a share of the gross profit from milling ore sourced from Talisker Resources Ltd. Blue Lagoon Resources Inc. (OTCQB: BLAGF, CSE: BLLG) recently announced an amended mining and milling partnership agreement with Nicola Mining, extending the partnership to a 10-year term. The agreement secures a long-term processing solution for mineralized material from Blue Lagoon’s high-grade Dome Mountain Gold Project.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Comstock (LODE) – Strategic Acquisition Expands Nevada Mining Footprint

Posted on by cpatches


Thursday, October 16, 2025

Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complimentary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit www.comstock.inc.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Acquisition of Haywood Quarry. Comstock completed the acquisition of the Haywood Quarry industrial and mineral properties from Decommissioning Services LLC. The 190-acre property, located in Lyon County, Nevada, includes available power, water, and direct access to U.S. Highway 50. The site historically hosted gold mining and aggregate operations and is strategically contiguous to Comstock’s flagship Dayton gold and silver resource.

Transaction terms. Comstock acquired the property for a total of $2.2 million in cash and stock from Decommissioning Services LLC. The transaction provides Comstock with full ownership and control of the Haywood industrial and mineral properties, integrating them into its broader Lyon County mineral estate. The purchase also enhances Comstock’s strategic flexibility in advancing mine planning, resource development, and reclamation initiatives at the Dayton complex.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – Highlights from the Noble Emerging Growth Virtual Conference

Posted on by cpatches


Thursday, October 16, 2025

ARLP is a diversified natural resource company that generates operating and royalty income from coal produced by its mining complexes and royalty income from mineral interests it owns in strategic oil & gas producing regions in the United States, primarily the Permian, Anadarko and Williston basins. ARLP currently produces coal from seven mining complexes its subsidiaries operate in Illinois, Indiana, Kentucky, Maryland and West Virginia. ARLP also operates a coal loading terminal on the Ohio River at Mount Vernon, Indiana. ARLP markets its coal production to major domestic and international utilities and industrial users and is currently the second largest coal producer in the eastern United States. In addition, ARLP is positioning itself as an energy provider for the future by leveraging its core technology and operating competencies to make strategic investments in the fast growing energy and infrastructure transition.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble virtual conference. Alliance recently participated in Noble Capital Markets’ Emerging Growth Virtual Conference. The fundamental outlook for ARLP’s coal operations and oil and gas royalty business, the two largest drivers of cash flow, remains favorable. The coal and electric power generation industries are expected to benefit from Trump Administration policies that seek to assure affordable, reliable, and secure energy sources to meet growing demand for electricity. Through 2Q 2025, Alliance has invested $758 million in its oil and gas royalty business that has generated cumulative segment adjusted EBITDA of $622 million. While they have grown the oil and gas royalty business without the use of leverage, they do have the ability to employ leverage for larger acquisitions. A link to the presentation is here.

Capital allocation. Management takes a long-term view when making capital allocation decisions, with balance sheet strength being the highest priority. The next priority is investing in its coal business to ensure it remains an efficient and low-cost producer. The third priority is reinvesting the cash flow generated by the oil and gas business to make accretive acquisitions. Lastly, the company intends to return capital to shareholders, including attractive cash distribution payments, while ensuring flexibility to fund growth opportunities.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Comstock Completes Acquisition of Haywood Quarry

Posted on by aweinsoff@channelchek.com

Research News and Market Data on LODE

VIRGINIA CITY, NEVADA, October 15, 2025 — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced that it has completed its purchase of the Haywood quarry industrial and mineral properties from Decommissioning Services LLC for a total of $2.2 million in cash and stock. The Haywood property totals approximately 190 acres in Lyon County, Nevada, and has available power, water, and easy access to US 50. These properties historically hosted gold mining and processing operations, and more recently, aggregate mining and are strategically located and contiguous to the Company’s Lyon County mineral properties, including our now flagship Dayton gold and silver resource.

“This is a very important addition to our mineral portfolio,” stated Mr. Corrado De Gasperis, Comstock’s Executive Chairman and CEO, “as it could conveniently host activities to support the mining at Dayton, and then provide post-mining industrial property in one of the largest industrial parks in Lyon County.”

The Comstock Lode was discovered in 1859. From 1860 to 1960, the district yielded more than eight million ounces of gold and 192 million ounces of silver, from workings greater than 3,000 feet below the surface. We have consolidated the most significant portions of the historic Comstock Lode mining district, conducted surface and airborne geophysical studies, drilled extensively, and developed detailed numerical models of the mineralization. We have secured permits, built an infrastructure, and completed two phases of test production. The Haywood Quarry is a strategic addition that enhances the efficacy of our Lyon County position.

Because of the Comstock Lode’s historical significance, the geology is well known and has been extensively studied. We have expanded our understanding of the geology through vigorous surface mapping and drill hole logging. The volume of geologic data is significant, particularly in the Lucerne and Dayton resource areas. We have accumulated a large library of historical data and detailed surface mapping of Comstock Mineral Estate properties and continue to obtain historical information from public and private sources. We have integrated this data with information obtained from our mining operations to target prospective geological exploration areas and plan exploratory drilling programs, including expanded surface and underground drilling.

The Company completed extensive geological mapping and drilling on a limited portion of our properties, particularly the Lucerne and Dayton resource areas, and characterized the mineralized material. We have performed metallurgical testing, mine planning and economic analysis while conducting extensive test mining operations, most recently from 2012 through 2016. The Company published an independent, third-party, S-K 1300 Technical Report Summary for our flagship Dayton gold and silver resources in November 2022. 

The Company’s 2025 efforts include applying economic analysis to our existing gold and silver resources progressing toward preliminary economic feasibility for the southern part of the district, that is the broader Dayton resource complex, and the ultimate development of full mine and reclamation plans and the development of post productive land and community development plans. 

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics. To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
Judd B. Merrill, Chief Financial Officer
Tel (775) 413-6222
ir@comstockinc.com

For media inquiries:
Zach Spencer, Director of External Relations
Tel (775) 847-7573
media@comstockinc.com

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; divestitures, spin-offs or similar distribution transactions, future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, divestitures, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

Release – Titan International, Inc. to Announce Third Quarter 2025 Financial Results on November 6

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TWI

Oct 15, 2025

CHICAGO, Oct. 15, 2025 /PRNewswire/ — Titan International, Inc. will release its third quarter 2025 financial results before the opening of the market on Thursday, November 6, 2025 to be followed by a teleconference and webcast on Thursday, November 6, 2025 at 9:00 a.m. Eastern Time.

The real-time, listen-only webcast can be accessed using the following link https://events.q4inc.com/attendee/328660313 or on our website at www.titan-intl.com within the “Investor Relations” page under the “News & Events” menu (https://ir.titan-intl.com/news-and-events/events/default.aspx).  Listeners should access the website at least 10 minutes prior to the live event.

In order to participate in the real-time teleconference, with live audio Q&A, participants should use the following dial in number:

United States (Toll-Free): 1 833 470 1428
All Other Locations:  https://www.netroadshow.com/conferencing/global-numbers?confId=56511
Participants Access Code: 973752

A webcast replay of the teleconference will be available on our website (https://ir.titan-intl.com/news-and-events/events/default.aspx) soon after the live event. 

About Titan : Titan International, Inc. (NYSE: TWI) is a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products.  Headquartered in West Chicago, Illinois, the company globally produces a broad range of products to meet the specifications of original equipment manufacturers (OEMs) and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. For more information, visit www.titan-intl.com.

Titan International, Inc. logo. (PRNewsFoto/Titan International)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/titan-international-inc-to-announce-third-quarter-2025-financial-results-on-november-6-302585132.html

SOURCE Titan International, Inc.

Release – SelectQuote’s Healthcare Select Research Uncovers Critical Gaps in Care, Highlighting Urgent Need for Personalized Healthcare Solutions

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SLQT

10/15/2025

Nearly 70% of Served Population Face Limited Access to a Local Pharmacy

OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT) (the “Company”), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today released a new research brief offering in-depth insights into the complex medical and social needs of the population it serves. The findings from tens of thousands of patient health needs assessments gathered by the Company’s Healthcare Select division highlight significant challenges across chronic care management, medication access, and financial security, underscoring the critical industry need for personalized, integrated healthcare solutions.

Key Research Findings:

  • Underserved Beneficiaries: Given that SelectQuote and Healthcare Select connect with beneficiaries telephonically, this population significantly over-indexes in historically-underserved areas lacking significant access to more traditional healthcare providers. 45% of Healthcare Select members reside in a rural zip code and 36% reside in an urban zip code, while only 11% reside in a suburban zip code.
  • Chronic Conditions: 74% of the population reported that they are dealing with two or more chronic conditions.
  • High Prescription Use: 75% of members regularly take 5 or more prescriptions.
  • Financial Headwinds: As 77% of SelectRx patients report annual household income of under $20,000, Social Determinants of Health often compound the treatment of health issues. 19% report having trouble accessing food on a regular basis. 36% indicate they are worried about being able to pay for bills if they were to face a serious illness.
  • Medication Delays: 16% of Healthcare Select members report having delayed taking medication for financial reasons.
  • Adherence Challenges: 40% of members have reported either forgetting to take their medications or failing to pick up prescriptions from a pharmacy. Independent studies indicate that failure to take medications consistently as prescribed (i.e., non-adherence) contributes to reduced treatment efficacy and poor disease control, higher rates of emergency department visits and hospitalizations, and increased morbidity and mortality.
  • Limited Pharmacy Access: Given their geographic concentration, approximately ⅔ of the population served by the Company’s SelectRx pharmacy reside in a “pharmacy desert” with limited access to local pharmacies.
  • Transportation: The headwinds to quality pharmacy access are exacerbated by the fact that 31% of Healthcare Select members report that they lack access to reliable transportation.

“This research provides a clear, data-driven look at the barriers to care faced by a large segment of the Medicare-eligible population,” said Bob Grant, SelectQuote President. “The high prevalence of chronic conditions, coupled with geographic and financial obstacles, illustrates why traditional one-size-fits-all healthcare is insufficient. We are committed to using this data to drive personalized solutions that effectively address these gaps.”

Mr. Grant continued, “We purpose-built Healthcare Select and our SelectRx pharmacy model to meet the needs of these underserved Medicare beneficiaries by combining telephonic outreach, personalized care coordination, direct prescription delivery, and packaging that improves adherence. By removing barriers like transportation and limited local pharmacy access, SelectRx helps patients manage complex medication regimens and improves adherence, ultimately driving better health outcomes.”

As Healthcare Select works to address members’ most pressing gaps in care — specifically in medication adherence, Social Determinants of Health, remote diagnostics and therapeutics, and chronic condition management — the Company actively seeks partners. SelectQuote invites innovative organizations and solution providers to connect with its Business Development team to collaboratively address these pressing issues impacting member care.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home™ (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select, which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com

Media:
Matt Gunter
913-286-4931
matt.gunter@selectquote.com

Source: SelectQuote, Inc.

Commercial Metals to Acquire Foley Products in $1.84 Billion All-Cash Deal

Posted on by cpatches

Commercial Metals Company (NYSE: CMC) announced it will acquire Foley Products Company, a leading supplier of precast concrete solutions in the southeastern United States, for $1.84 billion in cash. The move marks CMC’s formal entry into the precast industry and follows its recently announced acquisition of Concrete Pipe & Precast (CP&P).

CMC said the acquisitions of Foley and CP&P will establish the company as the third largest precast platform in the U.S., operating 35 facilities across 14 states, and a market leader in the Mid-Atlantic and Southeast regions.

“The acquisition of Foley presents a unique opportunity to create immediate scale for our precast platform while adding a best-in-class business with industry-leading margins to CMC’s portfolio,” said Peter Matt, President and Chief Executive Officer of Commercial Metals. “We believe precast has significant value creation potential for CMC, and the addition of Foley will help unlock further upside from our pending acquisition of CP&P.”

Foley Products is known for its industry-leading EBITDA margins and cash flow generation, supported by well-established best practices and a broad portfolio of precast solutions. The purchase price represents a 10.3x multiple of Foley’s forecasted 2025 EBITDA, or roughly 9.2x when factoring in expected cash tax benefits.

The transaction is expected to be immediately accretive to earnings per share and free cash flow, with $25 million to $30 million in annual run-rate synergies anticipated by the third year. Synergies will primarily stem from operational efficiencies, cost reductions, and cross-selling opportunities across complementary geographic markets.

Following the integration of Foley and CP&P, CMC expects its core EBITDA margin to increase by approximately 210 basis points, with about 32% of total pro forma segment adjusted EBITDA generated by its Emerging Businesses Group and precast platform — up from 15% in fiscal 2025. The company also expects strong free cash flow generation, targeting a reduction in net leverage from 2.7x to below 2.0x within 18 months.

CMC emphasized that the precast concrete market — estimated at $30 billion in annual U.S. revenue — provides a strong strategic fit, leveraging the company’s existing relationships in early-stage construction and expanding its reach into mission-critical infrastructure applications.

Precast components, such as concrete pipes and utility structures, are manufactured off-site in controlled environments, offering faster installation times, improved quality, and reduced labor needs compared to traditional pour-in-place methods.

Praxis Precision Medicines Reports Positive Topline Phase 3 Data for Ulixacaltamide in Essential Tremor, Shares Surge

Posted on by cpatches

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced positive topline results from its Essential3 Phase 3 program evaluating ulixacaltamide HCl for the treatment of essential tremor (ET). The company reported that both pivotal studies met their pre-specified primary endpoints, with all key secondary endpoints also achieved, and ulixacaltamide was generally well tolerated with no drug-related serious adverse events.

In the parallel-group study (Study 1), patients treated with ulixacaltamide demonstrated a mean improvement of 4.3 points from baseline in the Modified Activities of Daily Living 11 (mADL11) at Week 8 (p<0.0001). All key secondary endpoints, including rate of disease improvement over 12 weeks, Patient Global Impression of Change (PGI-C), and Clinical Global Impression of Severity (CGI-S), were statistically significant (p<0.001).

In Study 2, a randomized-withdrawal design, patients maintained superior treatment effects on ulixacaltamide versus placebo (p=0.0369), with the first key secondary endpoint — rate of disease improvement — also demonstrating a statistically significant benefit (p=0.0042).

“Patients in the Essential3 program had been living with essential tremor for an average of 30 years, with worsening symptoms and no effective treatment options,” said Marcio Souza, President and CEO of Praxis Precision Medicines. “The strong results underscore the large unmet need for a therapy like ulixacaltamide. We look forward to discussing a potential NDA with the FDA in the near term.”

The Essential3 program enrolled over 700 patients across two studies using a decentralized design in the United States. Study 1 was a 12-week, double-blind, placebo-controlled trial evaluating change in mADL11 at Week 8. Study 2 enrolled stable responders to ulixacaltamide and assessed maintenance of effect during a four-week randomized-withdrawal phase.

Ulixacaltamide is a selective T-type calcium channel inhibitor designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical circuit, which is associated with tremor activity. The therapy is the most advanced program in Praxis’ Cerebrum™ small molecule platform.

Essential tremor is the most common movement disorder in the U.S., affecting roughly 7 million people, and currently has limited treatment options. Propranolol is the only approved therapy, with limited efficacy and tolerability, leaving a substantial patient population untreated.

Following the announcement, PRAX shares surged more than 200% in early trading, with roughly 2.8 million shares traded, far exceeding the three-month daily average of 449,000 shares. Praxis has submitted a pre-NDA meeting request to the FDA and plans to continue advancing ulixacaltamide toward regulatory submission.

Release – Nicola Mining Announces Plan for 2026 Drilling Exploration at Treasure Mountain Silver Project

Posted on by aweinsoff@channelchek.com

Research News and Market Data on HUSIF

October 15, 2025 9:00 AM EDT | Source: Nicola Mining Inc.

Vancouver, British Columbia–(Newsfile Corp. – October 15, 2025) – Nicola Mining Inc. (TSXV: NIM) (OTCQB: HUSIF) (FSE: HLIA) (the “Company” or “Nicola“) is pleased to provide an update on preparation work conducted during 2025 on the Treasure Mountain Silver Project (“Treasure Mountain“) and its plan for 2026 exploration drilling program (“2026 TM Program“). The 2026 TM Program is the culmination of an airborne magnetic geophysical survey (conducted by Scott Hogg & Associates Ltd. in 2012), extensive soil sampling programs over multiple years, and 2025 field reconnaissance. Treasure Mountain is a permitted silver mine located 30 km northeast of Hope and about a 3-hour drive from Vancouver, British Columbia. Treasure Mountain was an operating mine but was put into care and maintenance in 2013[1], due to depressed silver prices and has always been a core asset to Nicola, which has been strategically waiting for higher silver prices.

As previously announced in the Company’s June 9, 2025 news release, Nicola received a multi-year area-based exploration permit (the “MYAB Permit“), allowing the Company to conduct diamond drilling and trenching at Treasure Mountain. In addition to receipt of MYAB Permit, the Company received a ten year mine lease extension (through April 26, 2032; announced on August 30, 2024), further bolstering the attractiveness of re-opening Treasure Mountain.

The area of exploration interest is northwest of the currently suspended mine (Fig. 1) and consists of several northeast-southwest trending and steeply dipping sulphide-rich veins (Fig. 2). Photos exhibited in Figure 2 are associated with 2025 field reconnaissance focused on establishing the 2026 TM Program drill targets.



Figure 1. Geological map of Treasure Mountain showing trend of mineralized veins northeast of the mine. 

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4873/270388_de6ad025542159aa_001full.jpg

Initial interest in this area was driven by Coeur Mining’s (“Coeur“)[2] (NYSE: CDE) (TSX: CDM) 2012 investment into the Company giving it a 12.7% ownership at time of investment. Coeur purchased shares at a price of $1.08 ($20.6 when considering subsequent rollbacks)[3].

Previous exploration work along this trend is limited to six percussion holes totaling 274m in 1994 and 14 “backpack drill” holes totaling 25m in 2020. Widespread soil sampling was also conducted in 2019 and 2020. Limited rock samples were collected in 2020 and 2021. The most recent exploration along this trend (sampling conducted by Nicola in 2021) is described in Assessment Report #39721 (available on ARIS[4]). Results from these programs are encouraging and demonstrate the presence of vein-hosted silver, copper, lead, zinc and gold. This provides support for initial diamond drilling to establish the width of the trend and mineralization at depth. Currently mineralization is present on surface and open in all directions.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/4873/270388_de6ad025542159aa_002.jpg

Figure 2. 2025 Field Reconnaissance Photos: (a) and (b) 10-20 cm wide quartz-sulphide veins steeply dipping and trending northeast-southwest. Close-ups of quartz veins show (c) mainly sphalerite with pyrite and chalcopyrite and (d) pyrite, chalcopyrite and sphalerite.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4873/270388_de6ad025542159aa_002full.jpg 

Cannot view this image? Visit: https://images.newsfilecorp.com/files/4873/270388_f8d245b9a405d91e_001.jpg

Figure 3. 3D magnetic MVI inversion at 200m depth below topography.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4873/270388_f8d245b9a405d91e_001full.jpg

Peter Espig, Chief Executive Officer, commented, “Recently we have garnered accelerated interest from both investors and strategics that have become increasingly excited about Treasure Mountain. At Nicola, we have always been aware of its significant potential, as highlighted by Coeur’s investment in the Company at a time prior to Nicola securing ownership of New Craigmont Copper Project and commencing gold production and pre-investment in Dominion Gold Project. In addition to these other projects, for the past decade we have continued to review, maintain and explore Treasure Mountain, which is more than an exploration project but is a fully permitted mine that can be reopened. We continue to review all possibilities and are excited for the 2026 TM Program.”

Qualified Person

The scientific and technical disclosures included in this news release have been reviewed and approved by Will Whitty, P.Geo., who is the Qualified Person as defined by NI 43-101. Mr. Whitty is Vice President of Exploration for the Company.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the TSX.V Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia It has signed Mining and Milling Profit Share Agreements with high grade gold projects. Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig“

Peter Espig
CEO & Director

For additional information

Contact: Peter Espig
Phone: (778) 385-1213
Email: info@nicolamining.com
URL: www.nicolamining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] Silver prices dropped below US$20 in 2013 and reached a low of US$13.80 in December of 2015. Link
[2] At the time of investment Coeur Mining was called Coeur d’Alene Mines Corporation
[3] July 17, 2014 (2 for 1), June 1, 2015, (5 for 1) and November 17, 2023 (2 for 1). The first 2 rollbacks were related to a successful CCAA process.
[4] British Columbia Geological Survey’s (BCGS) Assessment Report Indexing System

info

SOURCE: Nicola Mining Inc.

Release – Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GYRE

October 15, 2025

PDF Version

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that its indirect, majority-owned subsidiary, Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals), has completed patient enrollment in the 52-week Phase 3 clinical trial of its Class 1 drug, Pirfenidone capsules, for the treatment of pneumoconiosis.

A total of 272 patients have been enrolled in this multicenter, randomized, double-blind, placebo-controlled trial being conducted at 18 clinical research centers across China. The trial is designed to evaluate the efficacy and safety of 52 weeks of Pirfenidone capsule treatment in patients with pneumoconiosis, a chronic occupational lung disease characterized by progressive pulmonary fibrosis.

Unmet Medical Need in Pneumoconiosis

Pneumoconiosis remains the most common and severe occupational disease in China, with more than 450,000 surviving patients and thousands of new cases reported each year. It results from long-term inhalation of mineral dusts such as silica or coal, which triggers persistent inflammation and progressive fibrosis of the lung tissue. Over time, this excessive scar formation causes diffuse fibrosis and irreversible loss of lung function. Despite its prevalence and severity, there is currently no approved therapy in China that specifically targets the fibrotic mechanisms underlying pneumoconiosis.

Based on recent expert consensus, China’s pneumoconiosis treatment landscape represents a significant unmet medical need, underscoring the importance of developing therapies specifically designed to slow or halt the progression of fibrosis and improve long-term outcomes for affected patients.

About the 52-Week Phase 3 Trial

The ongoing trial compares Pirfenidone 1,800 mg/day (600 mg tid) with placebo over a 52-week double-blind treatment period.

  • Primary Endpoint: Change from baseline in forced vital capacity (FVC) % predicted at Week 52.
  • Key Secondary Endpoints: Changes in diffusing capacity of the lungs for carbon monoxide (DLCO), 6-minute walk distance, St. George’s Respiratory Questionnaire (SGRQ) score, and Modified Medical Research Council (mMRC) dyspnea scale, as well as rates of acute exacerbations, hospitalizations, and deaths.
  • Safety Monitoring: Follows Gyre’s Development Safety Update Report (DSUR Dec 2023–Dec 2024). Most adverse events reported to date are mild to moderate, with no unexpected safety signals.
  • Interim Analysis: None planned.

About Pirfenidone (ETUARY®)

Pirfenidone is an oral antifibrotic small molecule that received its original approval in China in 2011 by Gyre Pharmaceuticals for the treatment of idiopathic pulmonary fibrosis (IPF). It works by inhibiting TGF-β signaling and fibroblast proliferation. Gyre continues to advance Pirfenidone beyond IPF through multiple clinical programs, including the Phase 3 pneumoconiosis trial and the recently approved Phase 2/3 trial for oncology-related pulmonary complications such as radiation-induced lung injury (RILI) and checkpoint inhibitor pneumonitis (CIP).

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY®, and development programs for F573, F528, and F230.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the expectations regarding Gyre’s research and development efforts, including Gyre’s advancement of its Phase 3 trial in China for Pirfenidone capsules for the treatment of pneumoconiosis and the initiation of Gyre’s Phase 2/3 trial in China for Pirfenidone capsules for the treatment of RILI and CIP; and trial design of Gyre’s Phase 3 trial in China for Pirfenidone capsules for the treatment of pneumoconiosis. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings with the Securities and Exchange Commission.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

For Investors:
David Zhang
david.zhang@gyretx.com